Health Care·Biotechnology·$5.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.08 | N/A | -240.43% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.08 | N/A | -240.43% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, focusing on overcoming recent difficulties. They highlighted their ongoing efforts to stabilize operations.
Management acknowledged the challenges faced this quarter.
They emphasized their commitment to long-term strategies despite current setbacks.
CG Oncology Inc reported a significant loss per share, which was below expectations, indicating ongoing challenges for the company. Despite this, the stock rose by 4.79%, possibly due to investor optimism about future recovery efforts. The lack of revenue data and guidance leaves uncertainty about the company's immediate financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HOME DEPOT INC
Feb 24, 2026